Débridat

There is no image.

Trimebutine

Method of action: Drugs For Functional Gastrointestinal Disorders, Normalizing Bowel Motility, Regulating Tone And Motility Of The Gastrointestinal Tract

Treatment option: Gastroesophageal Reflux Disease, Bowel Obstruction, Burping, Irritable Bowel Syndrome

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Débridat

Quick Facts

Property	Description
Active ingredient	Trimebutine maleate
Form	Tablets, Oral suspension, Injection solution
Pharmacological class	Gastrointestinal motility regulator, Spasmolytic
General purpose	Normalization of gut movement and relief of associated discomfort
Origin	Synthetic compound

What is Débridat and What Type of Medicine is It?

Débridat is a prescription-only medicine primarily classified as a Gastrointestinal (GI) motility regulator and a Spasmolytic. Its core entity is the synthetic compound Trimebutine, which modulates the physical function of the digestive tract. The specific pharmaceutical salt, Trimebutine maleate, is globally recognized for its use in regulating gut movement.

This compound’s effectiveness in stabilizing movement distinguishes it from agents offering only pure spasm relief. Its action focuses on normalizing intestinal transit, validating its clinical designation as a regulator of gut function. Other preparations containing Trimebutine, such as Modulon, share this same therapeutic profile, emphasizing the compound's broad recognition for addressing functional gastrointestinal issues.

Composition and Available Pharmaceutical Forms

Débridat is formulated as a monosemantic drug, relying exclusively on Trimebutine maleate as its active ingredient. The substance is prepared using solid excipients for several dosage form(s), including standard oral tablets and specialized sustained-release tablets. The compound is also available as a solution for injection administered via the parenteral route, as well as granules for oral suspension suitable for both adults and pediatrics.

These varied pharmaceutical preparations ensure the compound can be administered effectively to target the source of the functional disturbance, supporting the drug’s capacity to achieve its intended, organ-specific action across the entire digestive system.

General Purpose and Action Profile

The general therapeutic purpose of Trimebutine is to help restore functional balance to the mechanical activity of the gut, providing relief from discomfort caused by irregular contractions. Its action profile features a key dual-action function, meaning it possesses the ability to both stimulate sluggish bowel movements and inhibit excessive, spastic contractions.

This adaptive effect on gut muscles is fundamental to its general benefit, stabilizing the rhythm of movement and overall intestinal transit. The use of Trimebutine is generally associated with scenarios where a patient's discomfort is directly linked to disorganized or unpredictable intestinal movement.

What side effects are possible with Débridat?

Possible Side Effects and Safety Information

The safety profile for Trimebutine maleate is officially documented through adverse reaction classifications and system-organ groupings. Regulatory documents generally classify reported adverse effects as Uncommon or as having a Not Known frequency, the latter meaning the incidence cannot be reliably estimated from available data (e.g., from post-marketing reports).

Official Adverse Reactions by System-Organ Class

The officially listed adverse reactions primarily involve the Gastrointestinal and Nervous Systems. Documented effects in these systems include nausea, dry mouth, vomiting, constipation, diarrhea, headache, and dizziness.

System-Organ Class	Common Adverse Reactions Listed
Gastrointestinal	Nausea, Vomiting, Dry Mouth, Constipation, Diarrhea
Nervous System	Headache, Dizziness, Somnolence (Drowsiness)
Dermatological	Rash, Pruritus (Itching)
Psychiatric	Anxiety, Confusion

Serious adverse reactions, though rare, are documented in official safety information. These include systemic hypersensitivity reactions, such as anaphylaxis, and severe cutaneous adverse reactions like Acute Generalized Exanthematous Pustulosis (AGEP). Reports of liver enzyme abnormalities and Hepatitis are also noted in post-marketing surveillance data.

Population and Formulation Safety Constraints

The medicine is contraindicated in patients with a known hypersensitivity to the active substance or any excipients. Use during pregnancy and lactation is generally not recommended due to a lack of established safety data. For the parenteral (injection) formulation, specific regulatory constraints exist, including contraindications for patients with a history of heart block or hypotension.

Overdose and Emergency Response

Débridat Overdose and when to seek help

Débridat (trimebutine) is generally considered to have a wide safety margin; however, cases of serious overdose, both accidental and intentional, have been reported in various age groups, particularly in young adults and infants. An overdose can lead to significant neurological and cardiac complications, requiring immediate medical attention.

Overdose Symptoms

Reported signs and symptoms of a trimebutine overdose can be severe and may include:

System	Reported Symptoms in Overdose
Neurological	Loss of consciousness, coma, excessive drowsiness, convulsions
Cardiovascular	Slowed heart rate (bradycardia), rapid heart rate (ventricular tachycardia), abnormally high blood pressure (arterial hypertension)
Other	Depressed respiration rate (in very high doses)

Time to symptom onset is often rapid, typically occurring within three hours of ingestion.

When to Seek Help

If you or someone else has taken more than the prescribed dose of Débridat, or if you suspect an overdose, it is essential to seek emergency medical care immediately, even if the individual does not yet show clear signs of toxicity. Treatment for an overdose is generally symptomatic and supportive, focusing on managing neurological and cardiac effects and maintaining vital functions. Contact your national emergency services or a poison control center right away.

Therapeutic Uses of Débridat

The therapeutic role of Débridat (Trimebutine maleate) is applied in addressing symptoms that interfere with the natural movement of the digestive tract, assisting with maintaining functional stability.

It is commonly used across conditions presenting with recurrent manifestations, such as Irritable Bowel Syndrome (IBS) and functional dyspepsia. The medication is applied across domains where additional symptomatic support is needed, relevant for managing symptom clusters that interfere with daily comfort. This includes abdominal cramping and pain, alternating patterns of diarrhea and constipation, and related functional disturbances. Applied in scenarios where additional management of discomfort is required, this medication can offer symptomatic relief and supports general well-being during symptomatic phases. The treatment is also relevant when supportive symptom management is appropriate, such as assisting with functional stability following post-operative abdominal surgery (paralytic ileus).

“This medication supports the patient during difficult episodes by easing distress and assists with maintaining functional stability when symptoms escalate temporarily.”

Quick Fact: Support for Functional Symptoms

Primary Use	Symptom Relief Focus	Patient Group Relevance
IBS and F-GID	Abdominal spasms, pain, and unpredictable transit	Adults, Children, Older adults

Regulatory References

Health Canada Product Monograph

Eligibility and Restrictions for Use

This section explains, based solely on authoritative regulatory documents, who is eligible and who is excluded from using medicines containing trimebutine maleate (marketed as Débridat in some countries).

Débridat is generally intended for adults who do not have any specific contraindications. Use is defined by the following limitations:

Contraindications (Must Not Use)

Classification	Population/Condition
Hypersensitivity	Patients with a known allergy or hypersensitivity to trimebutine maleate or any of the product's excipients.
Age	Contraindicated in children under 2 years of age (as per some product labels).

Use Restrictions and Special Considerations

Restriction Area	Official Eligibility Status
Age Restriction	Not recommended for use in children under 12 years of age (for some oral forms).
Pregnancy	Not recommended, particularly during the first trimester, due to insufficient human data. Use during the 2nd and 3rd trimesters is only considered if the potential benefit outweighs the risk.
Lactation (Breastfeeding)	Safety for use has not been established. It is generally advised to avoid use.
Excipient Intolerance	Formulations containing lactose are contraindicated for patients with rare hereditary problems such as total lactase deficiency, galactose intolerance, or glucose-galactose malabsorption.

These restrictions define the eligibility profile, formally excluding those with confirmed allergies and restricting use based on age and physiological status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Débridat (Trimebutine maleate) is characterized by the limited number of formally documented patterns cited in official regulatory sources. All interaction information is presented at a high, regulatory-aligned descriptive level, strictly based on government-approved product labeling.

Documented Pharmacodynamic Effects

The most specific interaction noted involves pharmacodynamic potentiation with certain agents used in general anesthesia. Regulatory documents state that co-administration of Trimebutine maleate has been shown in animal studies to increase the duration of curarization induced by d-tubocurarine, a non-depolarizing muscle relaxant. This effect reflects an additive influence on neuromuscular function.

Absence of Other Documented Interactions

Regulatory sources generally define the remainder of the product’s interaction landscape by the absence of other reported patterns and restrictions:

No other drug interactions have been formally observed during clinical trials or otherwise reported in the official product monograph.
No medicinal product combinations are listed as formally contraindicated due to interaction risk.
The labeling does not specify any clinically significant interactions driven by major metabolic pathways, such as CYP enzymes.
No mandatory timing rules are documented requiring the separation of doses from other medicines.
No warnings or restrictions are specified concerning concurrent use with food, alcohol, or herbal products.

Mechanism of Action

How Débridat Works

Trimebutine is a gastrointestinal motility modulator that acts through multiple, distinct mechanistic pathways to influence physiological regulation of the gut.

Modulation of Peripheral Opioid Receptors

Trimebutine acts as an agonist on peripheral mu (mu), kappa (kappa), and delta (delta) opioid receptors located within the enteric nervous system (ENS). This engagement modulates the release of neurotransmitters, influencing the excitation and inhibition of spontaneous gastrointestinal contractions, resulting in the modification of contraction frequency and amplitude.

Regulation of Intestinal Smooth Muscle Ion Channels

The molecule influences the membrane excitability of gastrointestinal smooth muscle cells by modulating various ion channels, primarily acting as an inhibitor of voltage-gated L-type calcium channels and certain potassium channels. This mechanism modifies the influx of calcium ions necessary for muscle contraction, resulting in the decrease of excitation-contraction coupling in smooth muscle cells and a reduction in hypermotility.

Desensitization of Visceral Afferent Signaling

Trimebutine influences afferent neural signaling in the gut, which is mediated by its action on ion channels, including sodium channels, thereby altering visceral afferent signal transmission. This mechanistic consequence changes the response of the enteric nervous system to internal physiological stimuli.

Dosage and Administration Information

Débridat, which contains the active ingredient trimebutine maleate, is a prescription medication used to normalize intestinal movement in patients with functional gastrointestinal disorders, such as irritable bowel syndrome (IBS). Always follow the specific dosing instructions provided by your healthcare professional.

General Administration Guidelines

Dosage: The recommended oral dosage for adults is typically 100 mg or 200 mg three times daily. This daily dose may be adjusted based on the patient's specific condition and response to treatment.
Timing: The tablets should generally be taken by mouth before meals. Taking the medication at the same times each day can help maintain regular usage.
Duration: Continue taking Débridat for the full duration prescribed by your doctor, even if your symptoms begin to improve.

Specific Use Considerations

Situation	Action to Take
Missed Dose	Take the missed dose as soon as you remember, unless it is nearly time for your next scheduled dose. If so, skip the missed dose and resume your regular schedule. Do not double the dose to compensate.
Overdose	Seek immediate emergency medical attention or contact a poison control center if you suspect an overdose.
Driving/Operating Machinery	Trimebutine may cause dizziness or drowsiness. Exercise caution and avoid driving or operating heavy machinery until you understand how this medication affects you.

Store this medicine at room temperature, away from light and moisture, and out of the sight and reach of children. Do not use the medication beyond the expiration date indicated on the packaging.

Recent Clinical Evidence

Research Evidence / Overview of Studies for [Drug Name]

Evidence for Use in Type 2 Diabetes Mellitus (T2DM)

Research has explored the use of this drug in adults with Type 2 Diabetes Mellitus across many Randomized Controlled Trials (RCTs). The studies examined primary health indicators such as HbA1 c levels (a measure of average blood sugar), fasting glucose, and changes in body weight. Study populations included individuals with a confirmed diagnosis of T2DM, and in certain research, this included patients dealing with established heart-related conditions. The findings describe patterns observed in the studies regarding the measurements of blood sugar indicators and how body weight was observed in the study populations over the trial duration.

Follow-up durations were limited in many cases, often focusing on short-term to intermediate-term changes. Certainty remains low when considering consistency in these measurements far beyond two years, as long-term effects are not fully established. Furthermore, data for certain groups remain insufficient, meaning the results apply most directly to the populations that participated in the research.

Evidence for Cardiovascular Risk Reduction

Dedicated Cardiovascular Outcome Trials (CVOTs) were conducted on patients with Type 2 Diabetes to specifically examine whether the drug was associated with patterns in the rates of major heart and stroke-related events (known as MACE). The patients included in these trials typically already had established heart disease or several other related risk factors. The research explored outcomes related to systemic or functional imbalance by monitoring the time until the first occurrence of events like heart attack, stroke, or cardiovascular death in the observed populations.

Limited information is available concerning the potential application for primary cardiovascular prevention in T2DM patients who do not have established disease. The research contributes to the broader evidence landscape by describing the group patterns observed, but the underlying reasons for the described findings are not fully established by the trials themselves.

What Is Still Uncertain About [Drug Name] Research

Despite the existence of several large-scale trials, there are ongoing areas of uncertainty. Evidence quality varies across studies depending on their size, design, and duration. Long-term effects are not fully established, particularly concerning the sustainability of the described findings over decades. The basis for the patterns observed in the studies regarding cardiovascular and kidney outcomes are not fully established by the trials themselves. Findings were mixed or inconsistent in some of the smaller, secondary outcomes, and data concerning certain types of adverse events are still emerging over time.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Débridat (FAQ)

Q: What should I do with my unused or expired Débridat?

Official regulatory guidelines instruct that this medicine should not be disposed of by flushing it down the toilet or throwing it into household waste. This is to ensure an environmentally safe disposal process. Patients are advised to consult a pharmacist about the proper method to discard the medicine according to local requirements.

Q: Are there any natural remedies or vitamins that are known to interact with Débridat?

According to the official product information and regulatory documents, there are no clinically significant interactions with food, alcohol, or herbal products that require specific warnings. Official product information does not specify any restrictions on concurrent use with these products.

Q: Can Débridat be used to treat acid reflux?

The approved regulatory indication for Débridat (trimebutine maleate) is the normalization of intestinal movement in patients dealing with functional gastrointestinal disorders, such as Irritable Bowel Syndrome (IBS). Acid reflux, or gastroesophageal reflux disease, is not included among the indications approved by regulatory bodies for this medication.

How should Débridat be stored and disposed of?

How to Store and Dispose of Débridat (Trimebutine)

Official regulatory labeling dictates strict conditions for the storage and disposal of Débridat to ensure its stability.

Storage Requirements

Débridat tablets must be stored below 30°C and away from heat, moisture, and direct sunlight. It is a mandatory requirement to keep this medicine out of the sight and reach of children.

Packaging and Stability: The medicine must not be used after the expiration date printed on the blister or carton. If using the oral suspension, the prepared liquid must be discarded after four weeks of storage.

Disposal Instructions

Unused or expired Débridat must not be thrown away via wastewater or household waste. To ensure environmentally safe disposal, individuals are instructed to ask a pharmacist how to properly discard the medicine according to local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.